
HeartBeam (BEAT) Stock Forecast & Price Target
HeartBeam (BEAT) Analyst Ratings
Bulls say
HeartBeam is attractive fundamentally because management has sharpened its strategy toward the larger myocardial infarction detection opportunity, while retaining a differentiated 12-lead patch platform that combines continuous rhythm monitoring with on-demand 12-lead ECG synthesis for a roughly $2B reimbursed market. The company’s pilot ALIGN-ACS study enrolled 132 adults and showed higher specificity with comparable sensitivity versus a standard 12-lead ECG, and positive FDA interaction has made management believe MI clearance could arrive by year-end 2027. Financially, 3Q net cash used in operations fell to $2.6 million, 23% below 2Q26 and 18% below last year’s 3Q, with FY26 operating cash outflow guided to $12 million to $12.5 million as the company raises additional capital to fund through 2027.
Bears say
HeartBeam is facing a weak fundamental setup because management has effectively postponed a large-scale arrhythmia commercialization strategy and redirected scarce resources toward an MI indication that still lacks clear approval timing, creating a long and uncertain path to meaningful revenue. Although the company has active pilot studies and a pre-submission request to the FDA, the critical hurdles remain clinical validation, algorithm development, and regulatory execution, while near-term commercialization is expected to stay limited. Financially, 2Q26 net loss was $5.0 million, operating cash outflow was $3.3 million, cash stood at $8.7 million at the end of June 2026, and the company may need additional capital within 12 months, heightening dilution and going-concern risk.
This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.
HeartBeam (BEAT) Analyst Forecast & Price Prediction
Start investing in HeartBeam (BEAT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About HeartBeam (BEAT) Forecast
HeartBeam (BEAT) Analyst Forecast & Price Prediction
Start investing in HeartBeam (BEAT)
Order type
Buy in
Order amount
Est. shares
0 shares